Metformin Hydrochloride Stada (Metformin Hydrochloride)

Metformin Hydrochloride is an oral antidiabetic agent used in the management of disorders related to impaired glucose regulation.

• Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose to improve glycemic control.
• Polycystic ovary syndrome (PCOS): reduces insulin resistance and may help restore ovulatory function.
• Prediabetes (impaired glucose tolerance): delays progression to overt type 2 diabetes by improving insulin sensitivity.

• Metformin Hydrochloride acts primarily by inhibiting hepatic gluconeogenesis, thereby decreasing endogenous glucose production. It also enhances peripheral glucose uptake in muscle and adipose tissue through activation of AMP‑activated protein kinase (AMPK), which improves insulin sensitivity. Additional effects include modest reduction of intestinal glucose absorption. These actions collectively lower circulating blood glucose without directly stimulating insulin secretion. The drug’s effect on the gut also contributes to its overall antihyperglycemic profile.

Metformin Hydrochloride may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, and diarrhea.
• Metallic taste: transient alteration of taste perception.
• Loss of appetite: reduced desire to eat.
• Weight loss: modest decrease in body weight.
• Vitamin B12 deficiency: decreased absorption with long‑term use.

Serious or Rare Side Effects

• Lactic acidosis: rare but potentially fatal accumulation of lactate.
• Severe hypoglycemia: usually when combined with other glucose‑lowering agents.
• Hepatotoxicity: liver enzyme elevations or injury.
• Skin reactions: severe rash or Stevens‑Johnson syndrome.
• Hemolytic anemia: rare in patients with G6PD deficiency.

When prescribing Metformin Hydrochloride, clinicians should observe several safety considerations.

• Renal function: assess creatinine clearance before initiation and periodically.
• Hepatic disease: avoid in patients with significant liver impairment.
• Cardiovascular status: use cautiously in patients with unstable heart failure.
• Age: monitor elderly patients closely for accumulation and adverse effects.
• Concomitant medications: review for drugs that may increase risk of lactic acidosis.
• Store at ambient temperature: keep below 25 °C in original container, protect from moisture.

Metformin Hydrochloride interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk.
• Cimetidine: can raise metformin plasma concentrations.
• Alcohol excess: enhances risk of lactic acidosis.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: may affect renal function, requiring dose adjustment.
• Diuretics: can reduce renal clearance of metformin.
• Beta‑blockers: may mask hypoglycemia symptoms.
• Certain antiretrovirals (e.g., protease inhibitors): may increase metformin levels.